Glucagon-like peptide 1 (GLP-1) and metabolic diseases (Q36309183)

13 August 2017

1 reference

title

Glucagon-like peptide 1 (GLP-1) and metabolic diseases (English)

1 reference

13 August 2017

C M Rotella

1

1 reference

PubMed ID

16277173

13 August 2017

L Pala

series ordinal

2

1 reference

PubMed ID

16277173

13 August 2017

E Mannucci

series ordinal

3

1 reference

13 August 2017

1 September 2005

1 reference

Journal of Endocrinological Investigation

13 August 2017

1 reference

13 August 2017

28

1 reference

13 August 2017

8

1 reference

13 August 2017

746-758

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03347560

13 August 2017

0 references

cites work

Mammalian pancreatic preproglucagon contains three glucagon-related peptides

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

GLP-1 release in man after lower large bowel resection or intrarectal glucose administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Gastric emptying and release of incretin hormones after glucose ingestion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

The effect of circulating non-esterified fatty acids on the entero-insular axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Elevated post-prandial gastric inhibitory polypeptide concentrations in hypertriglyceridaemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Cloning and functional expression of a human glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Signal transduction of the GLP-1-receptor cloned from a human insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Human glucagon-like peptide-1 receptor gene in NIDDM. Identification and use of simple sequence repeat polymorphisms in genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Internalization of glucagon-like peptide-1(7-36)amide in rat insulinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 receptor expression in Xenopus oocytes stimulates inositol trisphosphate-dependent intracellular Ca2+ mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Is glucagon-like peptide 1 an incretin hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 (7-36) amide administered into the third cerebroventricle inhibits water intake in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Candidate gene studies in pedigrees with maturity-onset diabetes of the young not linked with glucokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic -Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347560

Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate

21 January 2018

1 reference

12 December 2020

The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system

1 reference

12 December 2020

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

1 reference

12 December 2020

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

1 reference

12 December 2020

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line

1 reference

12 December 2020

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

12 December 2020

Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men

1 reference

12 December 2020

Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites

1 reference

12 December 2020

Glucagon gene expression in vertebrate brain

1 reference

12 December 2020

GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans

1 reference

12 December 2020

Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release

1 reference

12 December 2020

Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas

1 reference

12 December 2020

The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.

1 reference

12 December 2020

Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary

1 reference

12 December 2020

Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7-36 amide) stimulated by fat ingestion

1 reference

12 December 2020

Search for a third susceptibility gene for maturity-onset diabetes of the young. Studies with eleven candidate genes

1 reference

12 December 2020

A role for central glucagon-like peptide-1 in temperature regulation

1 reference

12 December 2020

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

1 reference

12 December 2020

Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats

1 reference

12 December 2020

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

12 December 2020

Absence of genetic variation in some obesity candidate genes (GLP1R, ASIP, MC4R, MC5R) among Pima indians

1 reference

12 December 2020

Isolation and structure of the principal products of preproglucagon processing, including an amidated glucagon-like peptide

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

1 reference

12 December 2020

The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity

1 reference

12 December 2020

Stimulation of rat parietal cell function by histamine and GLP-1-(7-36) amide is mediated by Gs alpha

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

The glucagon-like peptides

1 reference

12 December 2020

Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function

1 reference

12 December 2020

Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells

1 reference

12 December 2020

A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics

1 reference

12 December 2020

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors

1 reference

12 December 2020

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

1 reference

12 December 2020

Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice

1 reference

12 December 2020

Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells.

1 reference

12 December 2020

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

12 December 2020

Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects.

1 reference

12 December 2020

Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose

1 reference

12 December 2020

Solubilization of active GLP‐1 (7–36)amide receptors from RINm5F plasma membranes

1 reference

12 December 2020

Complete sequences of glucagon-like peptide-1 from human and pig small intestine

1 reference

12 December 2020

Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain

1 reference

12 December 2020

Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men

1 reference

12 December 2020

Incretin hormone expression in the gut of diabetic mice and rats

1 reference

12 December 2020

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1 reference

12 December 2020

Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6

1 reference

12 December 2020

Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor

1 reference

12 December 2020

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

1 reference

12 December 2020

Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition

1 reference

12 December 2020

Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347560

1 reference

13 August 2017

1 reference

PubMed ID

16277173